CRISPR Therapeutics (NASDAQ: CRSP)
CRISPR Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
There are a handful of different factors that could buoy its stock.
Is CRISPR Therapeutics a Millionaire Maker?
The stars are aligning for it to be a leader for years to come.
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These biotech stocks have just launched their first products.
Is CRISPR Therapeutics Stock a Buy?
The gene-editing therapy specialist is rising in prominence.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
How much would you pay for a stock that might earn $25 a year in six years?
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
It pays to develop novel medicines for life-threatening illnesses.
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Breaking Down CRISPR Technology
What investors need to know.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.